Evans John M.

CEO, DirectorBeam Therapeutics Inc. (BEAM) · full profile →Form 4 · filed Jul 1, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.7M
Net Open-Market Flow
-$1.7M
Transactions
10
7 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 30, 2026Option exercise(M)25K$1.03$26K1.1M
Jun 30, 2026Sell(S)23K$34.26$791K1.0M
Jun 30, 2026Sell(S)2K$34.84$66K1.0M
Jun 29, 2026Sell(S)12K$35.91$416K1.0M
Jun 29, 2026Option exercise(M)19K$0.67$13K1.1M
Jun 29, 2026Option exercise(M)6K$1.03$7K1.1M
Jun 29, 2026Sell(S)13K$35.13$472K1.1M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 30, 2026Option exercise(M)25K$0206K
Jun 29, 2026Option exercise(M)19K$09
Jun 29, 2026Option exercise(M)6K$0231K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-292526) within minutes of acceptance. Every field above traces to the original document. Verify it directly: